AKZO NOBEL NV
No enriched coverage for $AKZOY in the last 7 days.
No SEC Form 4 filings for $AKZOY in the last 30 days.
See all $AKZOY insider activity →Barclays upgraded Akzo Nobel to Outperform from Equal Weight, citing a Q2 earnings recovery in European chemicals. The bank said EBITDA beat expectations across the group and pricing turned positive year over year, which it viewed as improving performance versus prior periods.
Barclays upgraded Akzo Nobel N.V. to Overweight and raised its price target, according to the note cited in the article. The report references a composite rating framework based on valuation, EPS revisions, and visibility metrics.
Barclays upgraded Akzo Nobel N.V. to Overweight/Buy and raised its price target, citing a composite assessment based on valuation, EPS revisions, and visibility metrics. The article provides the stock’s recent trading level in EUR on Euronext Amsterdam.
Recent AKZOY coverage spans mergers & acquisitions, financial news and earnings.
The article is an analyst-upgrade catalyst tied to an earnings recovery narrative, but it provides no new company numbers beyond the upgrade thesis.
The article is an analyst rating and PT change for Akzo Nobel, which can drive near-term flows and relative-performance trades versus peers.
Analyst upgrade with a higher target can drive near-term relative outperformance, but the article provides no new company fundamentals beyond the call.
Deal momentum improves for AkzoNobel, but completion still hinges on regulatory approvals and customary closing conditions.
Approval at the Akzo Nobel EGM advances the merger process and improves the path to completion, subject to regulatory approvals.
alphai scores every news story that mentions AKZOY with an AI model for sentiment and relevance, and aggregates insider trades from AKZO NOBEL NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
Barclays upgraded Akzo Nobel to Outperform from Equal Weight, citing a Q2 earnings recovery in European chemicals. The bank said EBITDA beat expectations across the group and pricing turned positive year over year, which it viewed as improving performance versus prior periods.
2 min readBarclays upgraded Akzo Nobel N.V. to Overweight and raised its price target, according to the note cited in the article. The report references a composite rating framework based on valuation, EPS revisions, and visibility metrics.
1 min readBarclays upgraded Akzo Nobel N.V. to Overweight/Buy and raised its price target, citing a composite assessment based on valuation, EPS revisions, and visibility metrics. The article provides the stock’s recent trading level in EUR on Euronext Amsterdam.
1 min readAkzoNobel shareholders approved all resolutions for the proposed all-share merger with Axalta at an Aug. 5, 2026 extraordinary general meeting, including merger approval, share issuance, board appointments and remuneration policy. Axalta shareholders also voted in favor. The deal moves to regulatory review and other closing conditions, with completion expected end-2026 or early 2027.
2 min readAxalta Coating Systems and Akzo Nobel said shareholders approved their all-stock merger of equals at meetings on 5 Aug 2026. Akzo Nobel approved merger-related resolutions including share issuance, board appointments and remuneration policy, while Axalta approved the deal at its special meeting. Completion still depends on regulatory approvals and customary closing conditions, expected late 2026 or early 2027.
4 min readShareholders of Axalta Coating Systems and Akzo Nobel have approved their merger, according to the article. The piece also notes Axalta’s stock price at about $37.84 and references an RBC view that the company is tracking toward the 2026 EBITDA midpoint as strength in refinish and truck coatings builds.
1 min readAkzo Nobel and Axalta Coating Systems said they refined governance terms for their planned all-share merger of equals after shareholder dialogue. Changes include annual director re-election after an initial three-year period, and lowering a non-executive approval threshold from 75% to two-thirds for key decisions. No changes to the combined company articles or meeting agendas were required.
3 min readAkzo Nobel reported 5% organic growth in Q2 core profit, beating estimates. Adjusted EBITDA rose to €398m from €393m, above analysts’ €392m expectation, helped by previously announced price increases offsetting higher raw-material costs. CEO Greg Poux-Guillaume said differences were mainly due to divestment in India. The company also plans a merger with Axalta, with a shareholder vote on Aug 5.
3 min readAkzo Nobel shares rose 1.3% after the company reported Q2 adjusted EBITDA of €398 million, up 5% and above consensus (€392 million). Revenue was €2.59 billion. Akzo Nobel upgraded full-year adjusted EBITDA guidance to at least €1.47 billion vs prior €1.42 billion estimate, and reiterated its Axalta merger vote on Aug 5.
3 min readBernstein expects a largely solid Q2 earnings season for the chemicals sector, with limited guidance changes. It names Akzo Nobel its highest-conviction pick, arguing FY2026 EBITDA guidance cut expectations are too bearish (models €1.48B vs consensus ~€1.42B). It is cautious on Air Liquide and Solvay, citing elevated growth expectations and guidance-miss risk.
4 min read
